In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

@article{Ghielmini1998InVS,
  title={In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).},
  author={Michele Ghielmini and Emilia Colli and E. Gadioli Erba and Daniele Bergamaschi and Sandro Pampallona and J. L. Jimeno and Glynn Faircloth and Cristiana Sessa},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1998},
  volume={9 9},
  pages={
          989-93
        }
}
BACKGROUND Ecteinascidin (ET-743) is a marine derived compound with an interesting preclinical profile currently completing phase I clinical trials. The present study was undertaken to compare the toxicity of different schedules of ET-743 against human hemopoietic progenitors and tumour cell lines. MATERIALS AND METHODS Human hemopoietic progenitors and solid tumour cell lines were incubated with ET-743 for one hour, 24 hours and one hour daily for five consecutive days to define by… CONTINUE READING
Highly Cited
This paper has 23 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

A phase I and pharmacokinetic study of ET - 743 , a novel DNA minor groove binder of marine origin , administered as a one - hour infusion daily x 5 days

  • M Villalona-Calero, SG Eckardt, G Weiss
  • Ann Oncol
  • 1998

Ecteinascidin 743 ( ET - 743 ) 24 - hour continuous intravenous infusion phase I study in solid tumour patients

  • E Cvitkovic, B Mekranter, A Taamma
  • Ann Oncol
  • 1998

Effect of Ecteinascidin 743 (ET-743) on the interaction between transcription factors and DNA

  • L Mantovani, E LaValle, M Bonfanti
  • Ann Oncol 1998;
  • 1998
1 Excerpt

Incomplete crossresistance between Ecteinascidin 743 (ET-743) and standard chemotherapeutic agents against primary tumors in human tumor cloning assay

  • E Izbicka, R Lawrence, K Davidson
  • Ann Oncol
  • 1998
1 Excerpt

Phase I clinical and pharmacokinetic ( PK ) study of Ecteinascidin 743 ( ET - 743 ) given as a one - hour infusion every 21 days

  • A Bowman, C Twelves, K Hoekman
  • Ann Oncol
  • 1998

Antitumor effect of Ecteinascidin 743 (ET-743) on human ovarian carcinoma xenografts

  • G Valoti, MI Nicoletti, G Faircloth
  • Proc Am Assoc Cancer Res
  • 1997
1 Excerpt

NMR-based model of an Ecteinascidin 743-DNA adduct

  • BM Moore, FC Seaman, LH. Hurley
  • J Am Chem Soc
  • 1997
2 Excerpts

Similar Papers

Loading similar papers…